Device and method for promoting rapid strut coverage and vascular endothelial coverage

Abstract

Myosin heavy chain 11 (MYH11)-siRNA-eluting, calponin 1 (CNN1)- siRNA-eluting, leiomodin 1 (LMOD)-siRNA-eluting, smoothelin (SMTN)-siRNA-eluting, tropomyosin (TPM)-siRNA- eluting, caldesmon 1 (CALD)-siRNA-eluting, actinin (ACTN)-siRNA-eluting, actin alpha (ACTA)- siRNA-eluting, and actin beta (ACTB)-siRNA-eluting medical device capable of selective and significant inhibition of vascular smooth muscle cells (VSMC) in the same or even higher order of magnitude of sirolimus or analogs and paclitaxel or analogs that are cell antiproliferative drugs currently used in drug-eluting stents (DES), whereas said MYH11-siRNA-eluting, CNN1-siRNA-eluting, LMOD-siRNA-eluting, SMTN-siRNA-eluting, TPM-siRNA- eluting, CALD-siRNA-eluting, ACTN-siRNA-eluting, ACTA-siRNA-eluting, and ACTB-siRNA-eluting medicaldevices promote early medical device struts coverage and / or vascular re- endothelialization compared to the current DES that elute cell antiproliferative drugs such as sirolimus or analogs and paclitaxel or analogs.

Description

technical field [0001] The present invention relates generally to the field of medical devices, and more particularly to a device and method for facilitating rapid strut coverage and vascular endothelial coverage. Background technique [0002] Compared with bare metal stents (BMS), drug-eluting stents (DES) significantly reduce the incidence of restenosis, but significantly delay the speed of stent re-endothelialization and increase the incidence of stent thrombosis, so long-term use of dual antiplatelet therapy is required (DAPT) to reduce this high thrombosis rate. [0003] Consequently, DAPT duration increased from 30 days in the case of BMS to 12 months when DES was used. The long-term duration of DAPT has clinical and financial implications. [0004] Among these clinical effects, the risk of bleeding is increased, especially in patients prone to bleeding, such as recent history of gastrointestinal bleeding, hemorrhagic stroke, arteriovenous malformations, tumors, etc....

AI Technical Summary

Problems solved by technology

[0011] In the early 2000s, a major new breakthrough was achieved with the advent of DES, which significantly reduced the ISR; however, the DES significantly delayed stent re-endothelialization and, as a result, increased the rate of stent thrombosis, thereby prolonging the Duration of DAPT

Thus, as previously stated, this delay in stent re-endothelialization leads to serious negative clinical and financial impacts

Images